ESOPJun 11, 2026, 06:07 AM
Kiora Pharmaceuticals Stockholders Approve 1.5M Share Increase for Equity Plan
AI Summary
Kiora Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, where several key proposals were approved. Stockholders voted to amend the 2024 Equity Incentive Plan, increasing the number of shares available for issuance by 1,500,000. Additionally, three Class II Directors were elected, the compensation of named executive officers was approved on a non-binding advisory basis, and Haskell & White LLP was ratified as the independent registered public accounting firm for 2026.
Key Highlights
- Stockholders approved an amendment to the 2024 Equity Incentive Plan.
- The amendment increases the shares available for issuance by 1,500,000 shares.
- Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle were elected as Class II Directors.
- Executive officer compensation was approved on a non-binding advisory basis.
- Haskell & White LLP was ratified as the independent auditor for fiscal year 2026.
Price Impact
More from KPRX